Application
SC-236 has been used as a COX-2 inhibitor to study its effects on the mechano-reflex in rats.
Biochem/physiol Actions
SC-236 exhibits anti-tumor activity in gastric cancer cells by modulating activator protein-1 (AP-1) expression and by blocking the anchorage-independent cell growth. It also exhibits a protective effect against cartilage damage by minimizing the inflammation and pain in osteoarthritis. It is also reported to treat allergic inflammation.
SC-236 is a cyclooxygenase-2 (COX-2) inhibitor.
Other Notes
This compound was developed by Pfizer for Lipid Signaling research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
- UPC:
- 41116104
- Condition:
- New
- HazmatClass:
- Yes
- MPN:
- PZ0106-25MG
- CAS:
- 170569-86-5
akash.verma@cenmed.com
(732) 447-1115





